TRPC公司
TRPC1型
TRPC6型
缺氧性肺血管收缩
肺动脉高压
内科学
钙调神经磷酸酶
下调和上调
瞬时受体电位通道
血管收缩
血管舒张
内分泌学
细胞生物学
医学
化学
生物
受体
生物化学
移植
基因
作者
Junli Han,Hongyan Tian,Ya Liu,Fenling Fan
标识
DOI:10.14715/cmb/2018.64.13.17
摘要
Pulmonary arterial hypertension is caused by an imbalance of pulmonary vasoconstriction and vasodilation. Pulmonary arteriolar remodeling is a primary pathological change and proliferation of pulmonary arterial smooth muscle cells (PASMC) is an important pathological basis for pulmonary arteriolar remodeling. Vasoactive substances, such as 5-HT, may play a role in proliferation of PASMC via unknown mechanisms. In vitro experiments with PASMC showed that the TRPC channel inhibitor SKF96365 inhibited the effects 5-HT and DOI on PASMC proliferation and G2M percentage increase, and decreased expression of TRPC1, TRPC6 and calcineurin A/NFATc3 induced by 5-HT and DOI. SKF96365 inhibited binding of NFATc3 and DNA promoted by 5-HT and DOI. Therefore, 5-HT may affect the TRPC channel to promote proliferation of PASMC; upregulate expression of TRPC1, TRPC6, and calcineurin A/NFATc3; and therefore promote NFATc3 nuclear translocation. There may be crosstalk between 5-HT and TRPC, which may contribute to the pathogeneis of pulmonary arterial hypertension and this may be a novel therapeutic target for treating pulmonary arterial hypertension.
科研通智能强力驱动
Strongly Powered by AbleSci AI